OBJECTIVE: To determine whether baseline adiponectin levels or intervention-associated change in adiponectin levels were independently associated with progression to diabetes in the Diabetes Prevention Program (DPP). RESEARCH DESIGN AND METHODS: Cox proportional hazards analysis was used to evaluate the contribution of adiponectin and treatment-related change in adiponectin to risk of progression to diabetes. RESULTS:Baseline adiponectin was a strong independent predictor of incident diabetes in all treatment groups (hazard ratio per approximately 3 microg/ml higher level; 0.61 in the lifestyle, 0.76 in the metformin, and the 0.79 in placebo groups; all P < 0.001, P = 0.13 comparing groups). Baseline differences in adiponectin between sexes and race/ethnicity groups were not reflected in differences in diabetes risk. DPP interventions increased adiponectin levels ([means +/- SE] 0.83 +/- 0.05 microg/ml in the lifestyle group, 0.23 +/- 0.05 microg/ml in the metformin group, and 0.10 +/- 0.05 microg/ml in the placebo group; P < 0.001 for increases versus baseline, P < 0.01 comparing groups). These increases were associated with reductions in diabetes incidence independent of baseline adiponectin levels in the lifestyle and placebo groups but not in the metformin subjects (hazard ratio 0.72 in the lifestyle group (P < 0.001), 0.92 in the metformin group (P = 0.18), and 0.89 in the placebo group; P = 0.02 per approximately 1 microg/ml increase, P = 0.02 comparing groups). In the lifestyle group, adjusting for change in weight reduced, but did not remove, the effect of increased adiponectin. CONCLUSIONS:Adiponectin is a powerful marker of diabetes risk in subjects at high risk for diabetes, even after adjustment for weight. An increase in adiponectin in the lifestyle and placebo groups was associated with a reduction in diabetes risk. However, these changes in adiponectin were comparatively small and less strongly related to diabetes outcome than baseline adiponectin levels.
RCT Entities:
OBJECTIVE: To determine whether baseline adiponectin levels or intervention-associated change in adiponectin levels were independently associated with progression to diabetes in the Diabetes Prevention Program (DPP). RESEARCH DESIGN AND METHODS: Cox proportional hazards analysis was used to evaluate the contribution of adiponectin and treatment-related change in adiponectin to risk of progression to diabetes. RESULTS: Baseline adiponectin was a strong independent predictor of incident diabetes in all treatment groups (hazard ratio per approximately 3 microg/ml higher level; 0.61 in the lifestyle, 0.76 in the metformin, and the 0.79 in placebo groups; all P < 0.001, P = 0.13 comparing groups). Baseline differences in adiponectin between sexes and race/ethnicity groups were not reflected in differences in diabetes risk. DPP interventions increased adiponectin levels ([means +/- SE] 0.83 +/- 0.05 microg/ml in the lifestyle group, 0.23 +/- 0.05 microg/ml in the metformin group, and 0.10 +/- 0.05 microg/ml in the placebo group; P < 0.001 for increases versus baseline, P < 0.01 comparing groups). These increases were associated with reductions in diabetes incidence independent of baseline adiponectin levels in the lifestyle and placebo groups but not in the metformin subjects (hazard ratio 0.72 in the lifestyle group (P < 0.001), 0.92 in the metformin group (P = 0.18), and 0.89 in the placebo group; P = 0.02 per approximately 1 microg/ml increase, P = 0.02 comparing groups). In the lifestyle group, adjusting for change in weight reduced, but did not remove, the effect of increased adiponectin. CONCLUSIONS:Adiponectin is a powerful marker of diabetes risk in subjects at high risk for diabetes, even after adjustment for weight. An increase in adiponectin in the lifestyle and placebo groups was associated with a reduction in diabetes risk. However, these changes in adiponectin were comparatively small and less strongly related to diabetes outcome than baseline adiponectin levels.
Authors: Joachim Spranger; Anja Kroke; Matthias Möhlig; Kurt Hoffmann; Manuela M Bergmann; Michael Ristow; Heiner Boeing; Andreas F H Pfeiffer Journal: Diabetes Date: 2003-03 Impact factor: 9.461
Authors: Tobias Pischon; Cynthia J Girman; Gokhan S Hotamisligil; Nader Rifai; Frank B Hu; Eric B Rimm Journal: JAMA Date: 2004-04-14 Impact factor: 56.272
Authors: Utpal B Pajvani; Meredith Hawkins; Terry P Combs; Michael W Rajala; Tom Doebber; Joel P Berger; John A Wagner; Margaret Wu; Annemie Knopps; Anny H Xiang; Kristina M Utzschneider; Steven E Kahn; Jerrold M Olefsky; Thomas A Buchanan; Philipp E Scherer Journal: J Biol Chem Date: 2003-12-29 Impact factor: 5.157
Authors: L L N Husemoen; T Skaaby; T Martinussen; T Jørgensen; B H Thuesen; C Kistorp; J Jeppesen; J P Thyssen; M Meldgaard; P B Szecsi; M Fenger; A Linneberg Journal: Eur J Clin Nutr Date: 2013-11-13 Impact factor: 4.016
Authors: C Abbenhardt; A McTiernan; C M Alfano; M H Wener; K L Campbell; C Duggan; K E Foster-Schubert; A Kong; A T Toriola; J D Potter; C Mason; L Xiao; G L Blackburn; C Bain; C M Ulrich Journal: J Intern Med Date: 2013-03-29 Impact factor: 8.989
Authors: Erica P Gunderson; Catherine Kim; Charles P Quesenberry; Santica Marcovina; David Walton; Robert A Azevedo; Gary Fox; Cathie Elmasian; Stephen Young; Nora Salvador; Michael Lum; Yvonne Crites; Joan C Lo; Xian Ning; Kathryn G Dewey Journal: Metabolism Date: 2014-04-13 Impact factor: 8.694
Authors: Vanita R Aroda; Theodore P Ciaraldi; Paivi Burke; Sunder Mudaliar; Paul Clopton; Susan Phillips; R Jeffrey Chang; Robert R Henry Journal: J Clin Endocrinol Metab Date: 2008-11-04 Impact factor: 5.958